Spontaneous pneumothorax caused by anlotinib: 2 cases report
10.3760/cma.j.cn114015-20200316-00280
- VernacularTitle:安罗替尼致自发性气胸2例
- Author:
Yong WANG
1
;
Benjie SHAN
;
Xiabo SHEN
;
Dabing HUANG
Author Information
1. 中国科学技术大学附属第一医院（安徽省立医院）肿瘤内科，合肥 230001
- Publication Type:Journal Article
- Keywords:
Pneumothorax;
Drug-related side effects and adverse reactions;
Anlotinib
- From:
Adverse Drug Reactions Journal
2020;22(12):713-715
- CountryChina
- Language:Chinese
-
Abstract:
Two patients (patient 1, a 63-year-old female; patient 2, a 22-year-old male) were treated with anlotinib for lung adenocarcinoma and synovial sarcoma, respectively. Patient 1 developed cough, expectoration, and dyspnea after 8 cycles of anlotinib treatment (12 mg orally once daily, 2 weeks of treatment and 1 week of withdrawal as a treatment cycle). Spontaneous pneumothorax was diagnosed by chest CT. The spontaneous pneumothorax was considered to be related to anlotinib. Then the drug was stopped. After thoracic cavity closed drainage therapy, the patient′s dyspnea was relieved. Due to the progress of the disease, the patient received reduced-dose anlotinib treatment (10 mg/d, with the same usage as before). Spontaneous pneumothorax recurred in the first cycle. Anlotinib treatment was terminated and the symptomatic treatments including thoracic cavity closed drainage, expectorant, anti-infection, and nutritional support were given. Ten days later, chest X-ray examination showed that pneumothorax was cured. Patient 2 developed spontaneous pneumothorax (found by chest CT examination) after 9 cycles of treatment with anlotinib (12 mg/d, with the same usage as that in patient 1). But the patient had no obvious discomfort and continued to use anlotinib under close monitoring of respiratory status.
